Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Colombia BioPharmaceutical Approvals

Row Erupts Over “Third Way” For Biosimilar Approvals In Colombia

  • Analysis

Executive Summary

Colombia’s health ministry has accused the R&D-based pharmaceutical industry association of prioritizing monopolies over patients after its attempts to suspend legislation that promises a faster route to market for biosimilars.

You may also be interested in...



Belgium Aims To Drive Biologic Competition Through Tendering

New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.

Companies Need EU Funding To Cover ‘Enormous Expenditure’ Of Complying With Revised GMP Rules

Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.

IGBA Welcomes Mexican Membership

The IGBA has welcomed Mexican pharmaceutical industry association ANAFAM as an associate member.

Table

View full table

Topics

Tags:
Colombia BioPharmaceutical Approvals
Latest Headlines

And Then There Were 19: NurOwn Adcomm Loses Temporary Voting Member To Last-Minute Recusal

New EU Approvals

EU Needs Better Data Tools To Combat Vaccine-Preventable Cancers, Says Industry

Singapore To Require GMP Evidence On Chemical Substance Drug Manufacturers

See All
UsernamePublicRestriction

Register

PS121753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By